Rui Avelar
2023
In 2023, Rui Avelar earned a total compensation of $2.9M as Chief Medical Officer and Head of Research and Development at Evolus, a 132% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $320,610 |
|---|---|
| Option Awards | $691,957 |
| Salary | $487,750 |
| Stock Awards | $1,414,034 |
| Other | $14,827 |
| Total | $2,929,178 |
Avelar received $1.4M in stock awards, accounting for 48% of the total pay in 2023.
Avelar also received $320.6K in non-equity incentive plan, $692K in option awards, $487.8K in salary and $14.8K in other compensation.
Rankings
In 2023, Rui Avelar's compensation ranked 319th out of 3,006 executives tracked by ExecPay. In other words, Avelar earned more than 89.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 319 out of 3,006 | 89th |
Division Manufacturing | 177 out of 1,650 | 89th |
Major group Chemicals And Allied Products | 120 out of 918 | 87th |
Industry group Drugs | 117 out of 881 | 87th |
Industry Pharmaceutical Preparations | 74 out of 637 | 88th |
Source: SEC filing on April 26, 2024.
Avelar's colleagues
We found two more compensation records of executives who worked with Rui Avelar at Evolus in 2023.